# A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

> **NCT02720510** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Revlimid
- **DRUG:** Velcade
- **DRUG:** dexamethasone
- **DRUG:** Farydak

## Key facts

- **NCT ID:** NCT02720510
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-14
- **Primary completion:** 2017-05-22
- **Final completion:** 2017-05-22
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** A study was terminated due to low enrollment.
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720510, "A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02720510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*